

FIG. 1

Name	Kinetics			
	IL2RB KD (M)		IL2RG KD (M)	
	Human	Cyno	Human	Cyno
IL2RB_F09C**IL2RG_F16A	1.85E-08	1.07E-08	1.79E-09	4.87E-09
IL2RB_F09G**IL2RG_F16B	9.34E-08	1.67E-08	1.71E-08	5.02E-08
IL2RB_F09G**IL2RG_F16C	9.67E-08	1.60E-08	1.43E-09	3.58E-09
IL2RB_F09G**IL2RG_F18A	8.24E-08	1.73E-08	2.93E-09	5.81E-09
IL2RB_F09K**IL2RG_F16B	1.82E-07	1.65E-08	2.01E-08	4.15E-08
IL2RB_F18E**IL2RG_F16A	5.38E-08	5.52E-08	1.88E-09	5.42E-09

FIG. 3B

Cell Binding
Human CD8+ T-Cells





FIG. 3A

Cell Binding
Human CD4+ T-Cells



- IL2RB_F09C**IL2RG_F16A
- IL2RB_F09G**IL2RG_F16B
- IL2RB_F09K**IL2RG_F16B
- IL2RB_F09G**IL2RG_F16C
- IL2RB_F09G**IL2RG_F18A
- IL2RB_F18E**IL2RG_F16A
- IL2RB_F09C**IL2RG_F16B
- IL2RB_F09G**IL2RG_F16A

FIG. 3C
Cell Binding
Cyno CD8+ T-Cells




FIG. 4D

pSTAT5
Human CD56hi NK-Cells





FIG. 4C

pSTAT5
Human CD8+ T-Cells



- IL2RB_F09C**IL2RG_F16A
- IL2RB_F09C**IL2RG_F16B
- IL2RB_F09C**IL2RG_F16C
- IL2RB_F09C**IL2RG_F16A
- IL2RB_F09C**IL2RG_F16B
- IL2RB_F09C**IL2RG_F16C
- IL-2
- IL-2 Variant

FIG. 4E

pSTAT5
Cyno CD8+ T-Cells




FIG. 5B

Proliferation: Ki67%
Human CD4+CD25+ T-Cells





FIG. 5A

Proliferation: Ki67%
Human CD4+ T-Cells



- IL2RB_F09C**IL2RG_F16A
- IL2RB_F09G**IL2RG_F16B
- IL2RB_F09G**IL2RG_F16C
- IL2RB_F09G**IL2RG_F18A
- IL2RB_F09G**IL2RG_F18B
- IL2RB_F09G**IL2RG_F18C
- IL2RB_F09G**IL2RG_F18D
- IL2RB_F09G**IL2RG_F18E
- IL2RB_F09G**IL2RG_F18F
- IL2RB_F09G**IL2RG_F18G
- IL2RB_F09G**IL2RG_F18H
- IL2RB_F09G**IL2RG_F18I
- IL2RB_F09G**IL2RG_F18J
- IL2RB_F09G**IL2RG_F18K
- IL2RB_F09G**IL2RG_F18L
- IL2RB_F09G**IL2RG_F18M
- IL2RB_F09G**IL2RG_F18N
- IL2RB_F09G**IL2RG_F18O
- IL2RB_F09G**IL2RG_F18P
- IL2RB_F09G**IL2RG_F18Q
- IL2RB_F09G**IL2RG_F18R
- IL2RB_F09G**IL2RG_F18S
- IL2RB_F09G**IL2RG_F18T
- IL2RB_F09G**IL2RG_F18U
- IL2RB_F09G**IL2RG_F18V
- IL2RB_F09G**IL2RG_F18W
- IL2RB_F09G**IL2RG_F18X
- IL2RB_F09G**IL2RG_F18Y
- IL2RB_F09G**IL2RG_F18Z

FIG. 5C
Proliferation: Ki67%
Human CD8+ T-Cells

FIG. 5D
Proliferation: Ki67%
Human CD56+ NK Cells




FIG. 6A

Cytokine Release Assay

Human Whole Blood

FIG. 6B

Cytokine Release Assay

Human Whole Blood




FIG. 6C

Cytokine Release Assay
Human Whole Blood





FIG. 6D

Cytokine Release Assay
Human Whole Blood



- IL2RB_F09C**IL2RG_F16A
- IL2RB_F09G**IL2RG_F16B
- ▲ IL2RB_F09G**IL2RG_F16C
- ▼ IL2RB_F09G**IL2RG_F18A
- ◆ IL2RB_F09K**IL2RG_F16B
- IL2RB_F18E**IL2RG_F16A
- IL-2

FIG. 7A

Antibody Internalization
Human CD8+ T-Cells




FIG. 7B

Molecule	t _{1/2} (hr)
IL2RB_F09C**IL2RG_F16A	0.55
IL2RB_F09G**IL2RG_F16B	0.40
IL2RB_F09G**IL2RG_F16C	0.46
IL2RB_F09G**IL2RG_F18A	0.28
IL2RB_F09K**IL2RG_F16B	0.27
IL2RB_F18E**IL2RG_F16A	0.81

FIG. 8A




FIG. 8B

Molecule	Dose (mg/kg)	t1/2 (hr)
IL2RB_F09C**IL2RG_F16A	1	7.35
IL2RB_F09G**IL2RG_F16B	1	5.60
IL2RB_F09G**IL2RG_F16C	1	6.15
IL2RB_F09G**IL2RG_F18A	1	7.12
IL2RB_F09K**IL2RG_F16B	1	5.53
IL2RB_F18E**IL2RG_F16A	1	5.29

FIG. 9

Leads	Expression	Thermal Stability		Forced Degradation Stability	
	Yield (g/L)	Tm (°C)	Tagg (°C)	T0	T 1-month
IL2RB_F09C**IL2RG_F16A	0.5	58	57	1	2
IL2RB_F09G**IL2RG_F16B	0.3	62	60	1	1.5
IL2RB_F09G**IL2RG_F16C	0.4	62	60	0.4	18
IL2RB_F09G**IL2RG_F18A	0.1	63	61	0.6	2
IL2RB_F09K**IL2RG_F16B	0.3	62	59	1.0	1
IL2RB_F18E**IL2RG_F16A	0.1	62	61	0.6	3

FIG. 10A





FIG. 10B






FIG. 11A

CD8⁺ T-Cells




FIG. 11C

CD4⁺ T-Cells




FIG. 11B

CD3⁺CD159a⁺ NK-Cells





FIG. 11D

CD4⁺CD25⁺Foxp3⁺ T_{reg}s



● IL2RB_F09G**IL2RG_F16B (0.03mg/kg) ● IL2RB_F09G**IL2RG_F16B (0.1mg/kg) ● IL2RB_F09G**IL2RG_F16B (0.3mg/kg)
● IL2RB_F09C**IL2RG_F16A (0.03mg/kg) ● IL2RB_F09C**IL2RG_F16A (0.1mg/kg) ● IL2RB_F09C**IL2RG_F16A (0.3mg/kg)

FIG. 11E




FIG. 11G




FIG. 11F





FIG. 11H



● IL2RB_F09G**IL2RG_F16B (0.03mg/kg) ▨ IL2RB_F09G**IL2RG_F16B (0.3mg/kg)
■ IL2RB_F09C**IL2RG_F16A (0.03mg/kg) ▩ IL2RB_F09C**IL2RG_F16A (0.3mg/kg)

FIG. 11I




FIG. 11J




FIG. 11K




FIG. 12A




FIG. 12B

Molecule	Dose (mg/kg)	t1/2 (day)
IL2RB_F09K**IL2RG_F16B	1	5.28
IL2RB_F09K**IL2RG_F16B	10	5.1

FIG. 13




FIG. 14




FIG. 15B




FIG. 15A




FIG. 15C





FIG. 16A

FIG. 16B

Proliferation: Ki67%

Absolute Cell Concentration




- IL2RB_F09K**IL2RG_F16B (0.1 mg/kg)
- IL2RB_F09K**IL2RG_F16B (0.3 mg/kg)
- IL2RB_F09K**IL2RG_F16B (0.5 mg/kg)

FIG. 16C

Proliferation: Ki67%

FIG. 16D

Absolute Cell Concentration




- ▼ IL2RB_F09K**IL2RG_F16B (0.1 mg/kg)
- ◆ IL2RB_F09K**IL2RG_F16B (0.3 mg/kg)
- IL2RB_F09K**IL2RG_F16B (0.5 mg/kg)

FIG. 16E

Proliferation: Ki67%

FIG. 16F

Absolute Cell Concentration



- IL2RB_F09K~IL2RG_F16B (0.1 mg/kg)
- IL2RB_F09K~IL2RG_F16B (0.3 mg/kg)
- IL2RB_F09K~IL2RG_F16B (0.5 mg/kg)

FIG. 16G

Proliferation: Ki67%

FIG. 16H

Absolute Cell Concentration





FIG. 16I

Proliferation: Ki67%

FIG. 16J

Absolute Cell Concentration



- IL2RB_F09K**IL2RG_F16B (0.1 mg/kg)
- IL2RB_F09K**IL2RG_F16B (0.3 mg/kg)
- IL2RB_F09K**IL2RG_F16B (0.5 mg/kg)

FIG. 16K

Proliferation: Ki67%

FIG. 16L

Absolute Cell Concentration

